78 followers
Obesity in PCOs increases cardiometabolic risk.
Obesity in PCOs increases cardiometabolic risk.
Sodium-glucose cotransporter-2 inhibitors, can they decrease cardiovascular disease risk?
New Research: Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in… https://t.co/Fb9lGuzYlu